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The incidence of nasopharyngeal carcinoma (NPC) per 100 000 male population ranges from more than 20 in the Southeast Asian 
population to 0.5 in the white population.1 The histot
logic pattern, response to radiotherapy as well as surt
vival, vary markedly among different ethnic groups.2 
Nasopharyngeal carcinoma is a radiosensitive tumor and 
radiation therapy still remains the standard treatment. 
However, the results of conventional radiotherapy techt
niques and fractionations are unsatisfactory, especially 
for patients with advanced locoregional disease.3 The 
5tyear survival rates for patients with locally advanced 
NPC treated with radiotherapy alone are 10% to 40%.4,5 
Although new radiotherapy techniques have improved 
3t and 5tyear actuarial survival (75% and 56%, respect
tively)6 both locoregional and distant relapse are still the 
main causes of failure.7 
NPC is also a chemosensitive tumor and high ret
sponse rates have been achieved with many chemot
therapeutic agents, mainly cisplatin.8,9 After the interim 
analysis of the Intergroup Study 0099, which showed 
better survival in favor of chemoradiotherapy over rat
diotherapy alone (67% versus 37%, 5 year survival), 
chemoradiotherapy was considered the cornerstone of 
the standard care for locally advanced nasopharyngeal 
carcinoma.10 However, there are many uncertainties for 
chemoradiotherapy and its applicability to Asian pat
tients.3 In one of the Japanese studies, chemoradiotherat
py for locally advanced NPC was associated with severe 
acute side effects, poor compliance and outcome.11 We 
conducted this trial to determine the efficacy and feasit
bility of chemoradiotherapy in our Malaysian patients.
PATIENTS AND METHODS
This study included 30 patients with locoregionally 
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advanced nasopharyngeal carcinoma treated at the 
oncology and radiotherapy unit as well as at the ENT 
Department, Penang General Hospital, Malaysia, 
during the period between May 2004 and May 2006. 
Eligibility criteria included patients with N2/N3 and 
any T or T3/T4 and any N without distant metastases, 
according to the American Joint Committee on Cancert 
International Union Against Cancer staging system, 
1997,12 the World Health Organization histological 
grade IItIII, Eastern Cooperative Oncology Group 
(ECOG) performance status ≤2, age >18 years, with 
adequate bone marrow function (WBCs ≥3.5×109/L, 
platelets ≥100×109/L), renal function (creatinine cleart
ance >60 mL/min) and liver function (serum bilirubin 
<1.5mg/dL, transaminases <3 times the upper limit of 
normal), no previous treatment for NPC, and written 
consent to participate. Exclusion criteria were keratint
izing squamous cell carcinoma or adenocarcinoma, age 
>70 years, pregnancy or lactation, and prior malignancy 
(except adequately treated carcinoma in situ of the cert
vix or breast/ squamous cell carcinoma of the skin).
The pretreatment evaluation included a medical 
history, physical examination, full blood count with 
differential, and full biochemistry profile. Tumor stagt
ing was determined on the basis of clinical examinat
tion, nasopharyngoscopy, computed tomography of the 
head and neck, and chest xtray. Hepatic ultrasound was 
performed as indicated. A radionuclide bone scan was 
performed in patients with bone pain, elevated alkaline 
phosphatase, or N2/N3 disease.
All patients were assigned for concurrent chemorat
diotherapy. Cisplatin 30 mg/m2 mixed in normal saline 
was administered as a 30 minute infusion each Monday 
during the radiotherapy course. All patients received 
adequate hydration and a serotonin antagonist. Sixtyt
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six grays (Gy) were delivered in 3 phases. Phase 1 int
cluded 3 fields, right and left faciocervical (FC) and low 
anterior neck (LAN) fields. The FC fields delivered 40 
Gys/4 weeks/20 treatments using 6 MV. The upper 
border bisected the frontal sinus with proper shielding 
of the optic chiasma and brain stem. Two centimeters 
above the intracranial extension was allowed for T4 let
sions. The lower border was set as low as possible. The 
anterior border bisected the maxillary sinus, and for a 
nasal extension 2 centimeters anterior to that extension 
was allowed with shielding of both eyes. The posterior 
border included spinal accessory lymph nodes. The 
LAN field delivered 50 Gys/5 weeks/25 treatments as 
an applied dose. The upper border of LAN field was 
the lower border of the FC field using asymmetric jaw 
for matching. The inferior border was the medial end of 
both clavicles with shielding of the infraclavicular area. 
The lateral borders were set at the junction between the 
medial twotthirds and the lateral third of the clavicle. 
For phase 2, the cord was excluded and the posterior 
cervical lymph nodes bilaterally were treated for 10 
more Gys using 9t12 MeV prescribed to 90% isodose 
line, while the FC fields remained without changes and 
were treated with 6 MV for the same dose. For phase 
111, the palpable cervical lymph nodes were boosted 
using 9t12 MeV to deliver 16 Gy/1.5 weeks/8 treatt
ments. Also, the primary tumor plus 2 centimeters were 
boosted to the same dose using two lateral opposing 
fields with 10 MV. Two months after the completion of 
treatment, tumor response was assessed by clinical ext
amination, flexible nasopharyngoscopy and a CT scan 
of the head and neck. Treatment response and systemic 
toxicities were evaluated according to the WHO critet
ria.13 Followtup duration was calculated from the day 
of treatment to either the day of death or the day of last 
follow up. Pathologic confirmation of relapse was done 
whenever possible.
The primary end point of this study was to detert
mine the progressiontfree survival (PFS), while the 
secondary end points were to evaluate the objective ret
sponse rate and the safety profile of the combination. 
PFS was defined as the time from the first day of treatt
ment until the date of local failure, regional failure or 
distant failure.
 The KaplantMeier product limit method was used 
to calculate PFS.14 Recurrence rates were compared ust
ing the chitsquare test. The statistical significance of dift
ferences among survival curves was analyzed using the 
logtrank test.15 Prognostic factors related to PFS were 
assessed using a Cox proportional hazards regression 
model. All statistical tests were done using SPSS softt
ware version 10.
RESULTS
During the study period, 30 eligible patients were ent
rolled. Their mean (±SD) age was 47±12 years (median 
48 years, range 34t67 years).  Other baseline charactert
istics are shown in Table 1. The complete response rate, 
evaluated at 2 months after completion of treatment, 
was 80%, and the majority of the complete responders 
were stage III patients. After a median followtup of 18 
months (range, 10t30 months), 12 patients (40%) det
veloped tumor relapse. The distant failure was signifit
cantly higher in stage IV (Table 2). After median folt
low up of 18 months, all patients were still alive. The 
2tyear PFS rates were 70% and 30% for stages III and 
IV, respectively, and that difference was statistically sigt
nificant (Figure 1), while PFS was statistically insignifit
cant for either sex or different age groups (Figures 2, 3), 
respectively (P=.189, .2).
Acute toxic effects according to the World Health 
Organization criteria are listed in Table 3. All patients 
completed the proposed treatment, and there was no fat
tal toxicity related to the planned treatment. There was 
no impairment of renal function in our patients and no 
alopecia was noticed.
DISCUSSION
Nasopharyngeal carcinoma is one of the most comt
mon cancers in Malaysia, especially among the Chinese 
population, who have the highest agetadjusted incit
dence rates (40.1 per 100 000 for males and 14.9 per 
100 000 for females aged 40t49 years).16,17 The outcome 
of treatment with radiotherapy alone for locoregionally 
advanced NPC is poor,18,19 with high rates of both local 
and distant failures.20,21
NPC is a chemosensitive tumor and chemotherapy 
can be combined with radiotherapy in many ways (cont
comitant, adjuvant and neoadjuvant) in an attempt to 
improve the results.22,23 Many trials of adjuvant chemot
therapy have failed to improve the outcome. In a large 
randomized Italian trial with 229 patients, 6 monthly 
cycles of adjuvant vincristine, cyclophosphamide, and 
doxorubicin failed to improve the survival compared 
with patients receiving no adjuvant chemotherapy.24 
Another phase III study conducted in Taiwan showed 
no advantage either in overall survival (OS), or relapset
free survival (RFS) after use of 9 weekly cisplatin, 5tFU, 
and folinic acid after radiotherapy when compared with 
radiotherapy alone.25
Neoadjuvant chemotherapy has some advantages, 
such as decreasing the tumor burden, facilitating furt
ther radiotherapy and eradication of micrometastasis, 
but its impact on outcome is not clear. In a randomized 
trial, there was no survival benefit for patients with stage 
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Table 2. local and distant failures among stages iii and iV.
Variable Local failure Distant failure Local and distant
   Stage
     iii 3/19(16%) 2/19 (10.5%)* 2/19 (10.5%)**
     iV 2/11(18%) 5/11(46%)* 3/11 (27%)**
     iii, iV 5/30(17%) 7/30 (23%) 5/30 (17%) 
*P=0.045, **P=0.6
Table 3. Acute toxicity.
Toxicity Grade
0             1,2 3,4
leucopenia 18 (60%) 12 (40%) 0
Anemia 20 (66.7%) 10 (33.3%) 0
Mucositis 4 (13.4%) 20 (66.6%) 6 (20%)
Skin reaction 3 (10%) 22 (73.3%) 5 (16.7%)
Vomiting 12 (40%) 18 (60%) 0
IV tumor (N3M0) who had 3 cycles of neoadjuvant 
chemotherapy using vincristine, bleomycin, and epit
rubicin plus radiotherapy versus radiotherapy alone.26 
Another randomized trial using two or three cycles 
of neoadjuvant chemotherapy consisting of cisplatin, 
bleomycin, and fluorouracil did not show any survival 
benefit, although there was a trend for improvement of 
RFS favoring the neoadjuvant chemotherapy group.27 
Hareyama et al28 reported no significant improvement 
in either overall or diseasetfree survival after 2 cycles of 
neoadjuvant cisplatin and fluorouracil plus radiothert
apy versus radiotherapy alone. Concurrent chemorat
diotherapy has many advantages including a synergistic 
effect with radiotherapy, allowing no time for developt
ment of cross resistance, and no delay in the primary 
treatment.29,30 Radiotherapy with cisplatintbased chet
motherapy has been an important investigational subt
ject.31
In our study, the complete response rate was 80%, 
which is almost the same as reported by Wong et al,32 
who reported 86% and Zhang et al19 who reported 83% 
complete response (CR), while Lin et al29 reported 95% 
and Chan et al33 reported 97% CR. However, in Lin et 
al the radiotherapy dose was 70t74 Gy and chemothert
apy was a combination of cisplatin and 5 fluorouracil, 
while in Chan et al the radiotherapy dose was >75 Gy, 
so higher doses of radiotherapy and combination chet
motherapy may explain this better complete response 
rate.
After a median follow up of 18 months, the recurt
rence rate in our study was 40%, which is higher than 
that reported by Chan et al (28%, after 26 months met
dian follow up),33 Wong et al (39% after 34 months 
median follow up),32 Ong et al (14%, after 30 months 
median follow up)34 and Lin et al (26% after 65 months 
median follow up).29 In those studies the radiotherapy 
dose was >70 Gy  and they used combination chemot
therapy and not single agent therapy as in our study.
In our study the local failure for both stages III and 
IV was 17% while the distant failure was 23%.The local 
failure in our study was higher than has been reported 
by Chan et el33 who reported only 7% local failure. This 
could be explained by the higher dose used in Chan’s 
study as there is a relationship between dose and local 
control,33 while the distant failure was nearly identical 
(21% in Chan’s study). Lin et al29 reported lower lot
cal and distant failures (8% and 18%, respectively) due 
to use of high dose of radiotherapy and combination 
chemotherapy. In our study, the distant failure rate was 
higher in stage IV than stage III and the difference was 
statistically significant (P=.04), and consistent with 
Lin et al29 and Ong et al,34 but in contradiction to Chan 
Table 1.  patient characteristics.
Number of patients %
Race Chinese 26 86.7
Malay 4 13.3
Sex Male 23 76.6
Female 7 23.3
WHO grade ii 1 3.3
iii 29 96.7
T stage T1 6 20
T2 10 33.3
T3 9 30
T4 5 16.7
N stage n1 3 10
n2 18 60
n3 9 30
Stage iii 19 63.3
iV 11 36.7
Presentation local 2 6.7
nodal 25 83.3
both 3 10
ECOG, performance 
status
0-1 20 66.6
2 10 33.4
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Figure 1. Cumulative probability of progression-free survival for Stage iii and iV patients. (P=.005, hazard ratio=0.60, 95% Ci, 0.40-0.92).
Figure 2. Cumulative probability of progression free survival for male and females (P=.189, hazard ratio=1.04, 95% Ci, 0.64-1.71).
et al33 who reported no statistical difference.
After a median followtup of 18 months, all patients 
were still alive. In our study the 2tyear PFS was 70% 
for stage III and 30% for stage IV (Figure 1). Table 6 
summarizes trials for locally advanced NPC patients 
treated with concurrent chemoradiotherapy. Direct 
comparison of our results with others is not that easy, 
as most of the trials did not split PFS based on the dist
ease stage. In Chan et al, PFS (2 year, 76%) was better 
than our result, and this could be explained by inclut
sion of more advanced cases in our study (36% of our 
cases were stage IV, compared with 28% in Chan et al) 
, with the use of a lower dose of radiotherapy and the 
modest dose of cisplatin in our study. The rest of the 
studies did show better PFS (2 years 80% by Ong et al, 
3 years 72% by Wong et al, and 5 years 71.6% by Lin 
et al), and this is attributed to the use of combination 
chemotherapy as well as higher doses of radiotherapy. 
To our knowledge, there is no headttothead comt
parison between either induction or adjuvant chemot
therapy plus CCRT versus CCRT alone, but it seems 
that induction or adjuvant chemotherapy results are 
encouraging. Oh et al36 reported 92% 3tyear PFS with 
induction chemotherapy, while Altsaraf et al,3 Lee et 
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Figure 3. Cumulative probability of progression free survival for different age groups (P=.2, hazard ratio=1.03, 95% Ci, 0.68-1.67).
al,35 and Kwong et al,37 reported 69%, 70%, and 69.3%, 
3tyear PFS, respectively .
In the Cox regression analysis, PFS was not stat
tistically different for sex (P=.189) (Figure 2), or age 
groups (P=.2) (Figure 3), which is consistent with ret
sults from Chan et al,33 while Lee et al35 reported better 
PFS for females, and age <40 years. On the other hand 
PFS was significantly better for stage III than stage IV 
(Figure 1) (P=.005) and this is in agreement with Lee 
et al,35 but in contradiction to Chan et al.33 However, it 
is unclear if the improvement in PFS is due to the treatt
ment itself or due to the lack of routine imaging studies 
for exclusion of initial metastases, which might lead to 
underdiagnosis of failure.
In this study the compliance of our patients to the 
proposed treatment was very high. All patients comt
pleted the treatment without interruption, and only 
20% developed grade 3t4 mucositis and 17% developed 
grade 3t4 skin reaction. Our toxicity profile was better 
than in most of the trials. Chan et al33 reported 50% 
compliance and 50% grade 3t4 mucositis, while Lin et 
al29 reported 93% compliance, 45% grade 3t4 mucositis 
and 30% grade 3t4 skin reaction. Altsaraf et al3 reportt
ed 63% compliance. It is obvious that we have better 
tolerability because of a low dose of both radiotherapy 
and cisplatin, compared to higher doses of radiotherat
py, higher doses of cisplatin or use of combination chet
motherapy in other studies.
We can conclude from this study that CCRT is feat
sible in our patients, but the outcome is unsatisfactory. 
The dose of radiotherapy should be higher than 66 Gy 
and the concurrent chemotherapy should be a combit
nation. Since the results of adjuvant and neoadjuvant 
chemotherapy plus CCRT are superior to CCRT, this 
treatment should be tried. However, the compliance 
with adjuvant chemotherapy in the Intergroup Study 
was poor,3 so we believe neoadjuvant chemotherapy 
plus CCRT is warranted.
Table 4. Summary of phase iii studies of chemoradiotherapy for locally advanced nasopharyngeal carcinoma.
Study group Entry criteria Treatment Eligible cases
Median follow 
up (mo)
Progression-free 
survival
Current study AJCC/uiCC, 1997, stage iii, iV
CCrT, 66 Gy; cisplatin 30 mg/
m2/wk 30 18
2 y, 70%, for iii, 
30% for iV
lin et al29 AJCC/uiCC 1992 stage iii, iV CCrT>70 Gy, 2 cycles pF 141 65 5 y, 71.6%
Chan et al33 H0 n2-n3 CCrT >70 Gy, cisplatin 40 mg/m2/wk 175 31 2 y, 76%
wong et al32 Stage iii, iV CCrT>70 Gy paclitaxel, hydroxyurea, 5-Fu, 2 cycles 59 34 3 y, 72%
Ong et al34 Stage iii, iV CCrT >66 Gy, 5-Fu, cisplatin 14 30 2 y, 80%
CCrT=concurrent chemoradiotherapy, pF=cisplatin and 5-flourouracil, pHF=paclitaxel, hydroxyurea, 5-flourouracil pFS= progression-free survival
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